Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
7.68
-0.22 (-2.78%)
At close: Aug 4, 2025, 4:00 PM
7.66
-0.02 (-0.26%)
After-hours: Aug 4, 2025, 7:39 PM EDT

Company Description

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.

Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.

The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial.

In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; and CAP-2003, and allogeneic cardiosphere-derived cells-exosomes, which is in preclinical trial to treat DMD.

It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform.

The company was founded in 2005 and is headquartered in San Diego, California.

Capricor Therapeutics, Inc.
Capricor Therapeutics logo
CountryUnited States
Founded2005
IndustryBiotechnology
SectorHealthcare
Employees160
CEOLinda Marbán

Contact Details

Address:
10865 Road to the Cure, Suite 150
San Diego, California 92121
United States
Phone858 727 1755
Websitecapricor.com

Stock Details

Ticker SymbolCAPR
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001133869
CUSIP Number14070B309
ISIN NumberUS14070B3096
SIC Code2834

Key Executives

NamePosition
Dr. Linda Marbán Ph.D.Co-Founder, President, Chief Executive Officer and Director
Dr. Frank Isaac Litvack FACC, M.D.Executive Chairman of the Board
Anthony J. Bergmann M.B.A.Chief Financial Officer and Corporate Treasurer
Karen G. Krasney Esq., J.D.Executive Vice President, General Counsel and Secretary
Dr. Kristi A. H. Elliott Ph.D.Chief Operating and Science Officer
Minghao Sun Ph.D.Senior Vice President of Quality Control, Research and Product Development
Mark AwadallaChief Development Officer
Dr. Micheal Binks M.D.Chief Medical Officer
Catherine Lee KelleherConsultant

Latest SEC Filings

DateTypeTitle
Jul 29, 2025SCHEDULE 13GFiling
Jul 11, 20258-KCurrent Report
Jun 16, 2025S-8Securities to be offered to employees in employee benefit plans
May 27, 20258-KCurrent Report
May 14, 202510-QQuarterly Report
May 13, 20258-KCurrent Report
Apr 30, 2025SCHEDULE 13G/AFiling
Apr 9, 2025ARSFiling
Apr 8, 2025DEF 14AOther definitive proxy statements
Apr 8, 20258-KCurrent Report